Arrhythmia model using human induced pluripotent stem cells for drug safety testing
2013
SAIC-Frederick National Laboratory for Cancer Research, Frederick, USA
Cardiovascular liabilities of new chemical entities continue to be a significant source of attrition across the entire drug discovery and development process. Among the most common drug-induced cardiovascular findings encountered are disturbances in the electrical activity of the myocardium. Hence, novel screening models that are capable of incrementally improving the ability to assess a drug’s arrhythmogenic potential are needed. Human iPSC-derived cardiomyocytes (hiPS-CMs) have been shown to respond to known selective modulators similarly to a human heart. In the present study, the researchers assessed changes in the beat rhythm and rate of a confluent monolayer of hiPS-CMs by 118 compounds. This assay showed increased performance over existing preclinical tools in predicting clinical arrhythmia. In conclusion, hiPS-CMs are a relevant cell system to improve evaluating cardiac safety liabilities of drug candidates.
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model
Liang Guo
Added on: 11-29-2021
[1] https://academic.oup.com/toxsci/article/136/2/581/1681566[2] https://data.jrc.ec.europa.eu/dataset/20947a04-86ef-473f-8907-c658e4050c24
